Patients with rare cancers who are not able to receive standard treatment may be able to receive existing therapies designed for different cancers with the same genetic mutations, according to a novel study.
Browsing: Disease Area > Rare tumors
In this interview you can discover the current treatment options for mesothelioma as well as advancements that have been made in immunotherapy for this disease and what is being done to advance patient selection for this treatment modality.
In this article, the authors provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data.
In this patient perspective article, you can find out about the challenges associated with diagnosing mesothelioma and the promising role that biomarkers are playing.
Editor, Jade Parker recently spoke with world-renowned sarcoma expert, Robin L Jones. In this interview discover challenges in the diagnosis, treatment and clinical trials of sarcoma and other rare tumors.
Targeted sequencing focused on cancer-related genes provides comprehensive assessment of tumor mutational burden, with results comparable to whole-exome sequencing.
According to a new American Cancer Society Report, one in five cancer diagnoses in the United States is a rare cancer.
A commentry of brain tumors associated with Li-Fraumeni syndrome, followed by a case report of the development of a rare gliosarcoma in a Li-Fraumeni patient
Researchers have identified previously ignored mutations that, despite being rare, are likely associated with cancer growth. The discovery may lead to the development of new targeted therapies.
Lydia Makaroff of the European Cancer Patient Coalition (ECPC, Brussels, Belgium) speaks with Oncology Central about the goals and upcoming projects for the ECPC in 2017.